BU-NOT-SET

CONTACT US
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
  • Manufacturing
Eyes
Insight
Recipharm 25 years
  • Corporate
24 years
Brochure
API product list
  • Drug substance
white pills
Fact sheet
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
  • Drug substance
Eyes
Insight
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
  • Industry trends
Eyes
Insight
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Outsourcing stability testing
  • Analytical chemistry
Eyes
Insight
Insight
  • Drug product
Evolving strategies in oral solid dosage development
Case study
  • Sustainability
Sustainable pharmaceutical packaging
Webinar
  • Drug product
  • Manufacturing
Webinar | Bringing High Potent Drugs to Market
White paper
  • Drug product
  • Manufacturing
IVPT Strategies for reliable bioequivalence assessment
White paper
  • Biologics
  • Manufacturing
Recipharm Advanced Bio Is Advancing Optimizing TFF for RNA
Case study
  • Drug product
  • Manufacturing
Accelerating an innovative high potency oncology therapy to market
Insight
  • Manufacturing
When OSD manufacturing goes global
Insight
  • Drug product
  • Manufacturing
Ensuring Reliable HPAPI Supply
Insight
  • Drug product
  • Manufacturing
De-risking high-potency programmes